ASPEN PHARMACARE HOLDINGS LIMITED - Further announcement regarding the acquisition from MSD of a portfolio of products by Aspen

Further announcement regarding the acquisition from MSD of a portfolio of products by Aspen

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number: 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
(“Aspen Holdings”)




FURTHER ANNOUNCEMENT REGARDING THE ACQUISITION FROM MSD OF A PORTFOLIO OF PRODUCTS BY
ASPEN

Shareholders are referred to the announcement released by Aspen Holdings on 27 June 2013 wherein it
was confirmed that Aspen Global Incorporated had, amongst other things, reached an agreement on an
option (“the Option”) to acquire a portfolio of eleven branded finished dose form molecules (“the
Products”) from MSD, covering a diverse range of therapeutic areas.

Aspen Holdings is pleased to announce that Aspen Global Incorporated has exercised the Option. Subject
to the fulfilment of certain conditions precedent the effective date of the Product transaction resulting
from the exercise of the Option will be 31 December 2013.

Durban
31 October 2013

Underwriters
The Standard Bank of South Africa Limited
Bank of America, N.A.

Mandated Lead Arrangers and Bookrunners
The Standard Bank of South Africa Limited
Banc of America Securities Limited

Sponsor:
Investec Bank Limited

Date: 31/10/2013 12:00:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.